Mpox severity and mortality in the most endemic focus in africa: a systematic review and meta-analysis (1970-2024)

Fabrice Zobel Lekeumo Cheuyem[1,2]*, Armel Zemsi[3], Jonathan Hangi Ndungo[4], Chabeja Achangwa[5], Davy Roméo Takpando-le-grand[6], Jessy Goupeyou-Youmsi[2], Solange Dabou[2], Mohamadou Adama[1], Ariane Nouko[1], Marie Angèle Mbang[7], Edwige Omona Guissana[8], Rick Tchamani[9], Vanessa Monique Mballa Assiene[10], Ethel Eno[11], Constantine Tanywe Asahngwa[2], Saralees Nadarajah[12]

[1] Department of Public Health, Faculty of Medicine and Biomedical Sciences, The University of Yaounde I, Yaounde, Cameroon

[2] Division of Health Policy and Research, Nkafu Policy Institute, Denis and Lenora Foretia Foundation, Yaounde, Cameroon

[3] MRCG at LSHTM, Banjul, The Gambia

[4] Higher Institute of Medical Techniques, Bunia, Democratic Republic of Congo

[5] Department of Public Health, Faculty of Medical Sciences, University of West Indies, Cave Hill, Barbados

[6] Field Coordinator Frontline Field Epidemiology Training Program, Bangui, Central African Republic

[7] Division of Vaccination, Department of Family Health, Ministry of Public Health, Yaounde, Cameroon

[8] Department of Family Health, Ministry of Public Health, Yaounde, Cameroon

[9] Rosière Higher School of Health Sciences, Yaounde, Cameroon

[10] Public Health Emergency Operations Coordination Centre, Yaounde, Cameroon

[11] Women in Global Health, Yaounde, Cameroon

[12] Department of Mathematics, University of Manchester, Manchester, UK

*Corresponding author's address: Fabrice Zobel Lekeumo Cheuyem, Department of Public Health, Faculty of Medicine & Biomedical Sciences, The University of Yaounde I, Yaounde, Cameroon. Tel: +237 696 57 28 07; E-mail: zobelcheuyem@gmail.com

Abstract

Background Mpox, caused by the Mpox virus, is a zoonotic disease historically endemic in Central and West Africa. The Democratic Republic of Congo (DRC) bears the highest burden, with evolving epidemiology and significant public health challenges. Understanding severity and mortality trends is critical for global control efforts.

Methods This systematic review and meta-analysis followed PRISMA guidelines to synthesize evidence on Mpox severity and mortality in the DRC from 1970 to 2024. We searched PubMed, ScienceDirect, Web of Science identifying 22 eligible studies after screening 127 records. Data on confirmed and suspected cases, severe outcomes, and deaths were extracted. Random-effects models addressed high heterogeneity (I^2 > 75%), and subgroup analyses examined temporal trends (pre-1980 to 2024), regional differences (Western/Central vs. Eastern DRC), and healthcare settings (community vs. hospital). Meta-regression explored sources of heterogeneity, adjusting for study year, region, method, setting and design.

Results The pooled severity rate among 3,282 confirmed cases was 42.82% (95% CI: 31.60-54.05), declining from 68.58% pre-1980 to 27.55% in 2022-2024. Western/Central regions had higher severity (46.81%) than Eastern regions (42.66%). Case fatality rates (CFRs) were 1.89% (95% CI: 1.39-2.40) for suspected cases and 4.18% (95% CI: 0.29-8.08) for confirmed cases, with Western/Central DRC again disproportionately affected (CFR: 11.37%). Community settings showed higher CFRs (6.66%) than hospitals (0.64%), underscoring healthcare access disparities. Meta-regression confirmed study year (p < 0.001), and region as significant predictors of

outcomes heterogeneity (p = 0.03), with mortality declining over time but remaining elevated in resource-limited areas.

Conclusion Mpox continues to impose a substantial burden in the DRC, with high severity and mortality rates, particularly in Western/Central regions and community settings. The observed temporal decline in severity and CFRs suggests the impact of strengthened surveillance and healthcare capacity. However, regional disparities persist, driven by inequitable healthcare access and potential differences in viral clades. Targeted interventions, including vaccination in high-risk areas, community education, and mobile health units, are urgently needed. Global collaboration must address diagnostic and treatment gaps in endemic countries to prevent cross-border outbreaks.

Keywords epidemiology, Mpox, monkeypox, severity, mortality, Democratic Republic of Congo, systematic review, meta-analysis

Background

Monkeypox (Mpox), caused by the Mpox virus, is a zoonotic infection that has garnered increasing global attention due to its evolving epidemiology [1]. The Mpox virus belongs to the *Orthopoxvirus* genus, which also includes variola virus (the causative agent of smallpox), vaccinia virus (used in the smallpox vaccine), and cowpox virus [2]. Mpox virus is a double-stranded DNA virus with two distinct genetic clades: clade 1 (formerly known as the Congo Basin clade) and clade 2 (formerly the West African clade). Clade 1 has historically been associated with more severe disease and higher mortality rates compared to Clade 2 [3].

While historically concentrated in Central and West Africa, recent outbreaks have demonstrated its capacity to spread beyond endemic regions, posing a significant threat to global public health [4]. In the Democratic Republic of Congo (DRC), Mpox has been recognized as a public health threat since 1997, leading to the establishment of the National Program for the Control of Mpox and Hemorrhagic Fevers and the designation of Mpox as an epidemic-prone disease requiring immediate and mandatory notification [5]. The retrospective analysis of national routine surveillance data from 2010 to 2023 shows a concerning rise in Mpox incidence and geographical spread in the DRC. Over that period, the incidence rate rose from 2.97 to 11.46 per 100,000 people, with 60,967 suspected cases and 1,798 deaths reported, and children under 5 years were particularly affected [6].

The clinical pattern of Mpox infection is a characteristic skin rash, progressing through stages of macules, papules, vesicles, and pustules, eventually forming crusts [7]. This rash can be accompanied by systemic symptoms such as fever, headache, lymphadenopathy, and myalgia [8].

The severity of Mpox infection can vary widely, ranging from mild, self-limiting illness to severe or grave disease requiring hospitalization and leading to complications [9].

The transmission of Mpox virus to humans can occur through various routes [10]. Zoonotic transmission involves contact with infected animals, such as rodents and non-human primates [11,12]. Human-to-human transmission primarily occurs through close contact with infectious skin lesions, respiratory droplets, or contaminated materials. Sexual transmission has also been documented, particularly in recent outbreaks [3,13].

The epidemiology of Mpox has been significantly shaped by the global eradication of smallpox [1]. Smallpox vaccination, using vaccinia virus, provided cross-protective immunity against other *Orthopoxviruses*, including Mpox virus [14]. Following the cessation of smallpox vaccination campaigns, susceptibility to Mpox increased in the population, leading to a rise in Mpox incidence and a shift in its epidemiology [15].

Socioeconomic factors play a crucial role in shaping Mpox epidemiology in the DRC [8]. Poverty, limited access to healthcare, inadequate sanitation, and cultural practices can increase the risk of Mpox transmission and exacerbate its impact [16]. In addition, social instability and conflict can disrupt healthcare services and hinder disease control efforts [17].

The healthcare system in the DRC faces significant challenges, including limited infrastructure, shortages of healthcare workers, inadequate diagnostic capacity, and logistical difficulties in reaching remote areas [16]. These challenges can result in delayed diagnosis, inadequate treatment, and increased mortality from Mpox [18].

In light of the ongoing public health importance of Mpox in the DRC and its potential for global spread, it is imperative to enhance our understanding of the disease's severity and mortality patterns. Accurate and up-to-date information on these key epidemiological parameters is essential for informing evidence-based public health interventions and allocating resources effectively. This systematic review and meta-analysis aimed to address this critical need by synthesizing available data on Mpox severity and case fatality rates (CFRs) in the DRC. By examining trends over time and variations across different settings and populations, this study provides valuable insights into the current and historical burden of Mpox in the region, contributing to global efforts to control and mitigate the impact of this emerging infectious disease.

Methods

Study design

This study was conducted to assess the epidemiology the Mpox outbreak in DRC from 1970 to 2024. The study results are reported based on the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines [19].

Study setting

The DRC is the largest country in Sub-Saharan Africa, occupying a vast land area of approximately 2,345,409 km^2 [20]. Administratively, the DRC is divided into 26 provinces, including Bas-Uélé, Équateur, Haut-Katanga, Haut-Lomami, Haut-Uélé, Ituri, Kasaï, Kasaï-Central, Kasaï-Oriental, Kinshasa, Kongo Central, Kwango, Kwilu, Lomami, Lualaba, Mai-Ndombe, Maniema, Mongala, Nord-Kivu, Nord-Ubangi, Sankuru, Sud-Kivu, Sud-Ubangi, Tanganyika, Tshopo, and Tshuapa. The country's health system is organized into central, intermediate, and

operational levels. At the operational level, there are 519 health zones, 393 general referral hospitals, and 8,504 health areas [21]. The population is estimated to be over 105 million, with a median age of 16.7 years, a population growth rate of 3.1%, and a life expectancy of 61.6 years [22]. The health landscape is plagued by recurrent disease outbreaks, such as mpox, yellow fever, polio, cholera, measles, and Ebola [23]. The majority of the population is Christian, with over 93% identifying as such, of which 42% are Catholic [24]. The majority of the population is Christian, with over 93% identifying as such, of which 42% are Catholics [25]. The DRC has a long history of armed groups steering civil unrest, resulting in a complex humanitarian emergency [26].

Eligibility criteria

This systematic review and meta-analysis encompassed all published and unpublished research, regardless of study type or design, that documented Mpox severity and mortality rates in the DRC. Studies without clearly defined outcome variables were excluded. Prior to data extraction, duplicate articles were identified and removed. Only articles published in English or French were included, and no temporal restrictions were imposed on the publication date.

Article searching strategy

A methodical investigation of digital repositories, encompassing PubMed, Web of Science, ScienceDirect, and Google Scholar, was performed to locate published research. The search approach involved examining the words within the title and abstract of each study. A synthesis of keywords and Medical Subject Headings (MeSH) vocabulary was utilized, employing Boolean logic operators ("AND" and "OR") to narrow the search. The keywords and MeSH vocabulary included "monkeypox" OR "Mpox" OR "mpox infection" OR "human monkeypox" OR

"monkeypox virus" or “MPX” OR "mortality" OR "fatality" OR "severity" OR “death” OR "characteristics" OR "clinical characteristics" AND “Democratic Republic of the Congo" OR "DRC." OR “Zaire”. To ensure thoroughness, a manual search was conducted to identify additional relevant publications not found in electronic databases. Additionally, the reference lists of identified studies were screened to identify further relevant articles. The concluding search was performed on February 27, 2025.

Data extraction

Data were extracted from all eligible articles using a predefined Microsoft Excel 2016 form to collect study characteristics. The data extraction checklist included the first author’s name, study year, region, study design, type of study, setting, number of suspected, confirmed, severe and death cases. Two authors independently assessed each article for relevance and quality. Discrepancies between reviewers were resolved through discussion with a third reviewer to achieve consensus.

Data quality assessment

The quality of included studies was assessed using the Joanna Briggs Institute (JBI) quality assessment tool for case reports, case series, and cross-sectional studies [27]. Risk of bias was evaluated using eight to ten criteria, depending on the study design. (1) For cross-sectional studies, criteria included: appropriateness of the sampling frame, use of a suitable sampling technique, adequate sample size, description of study subjects and setting, sufficient data analysis, use of valid methods for identifying conditions and measurements, use of appropriate statistical analysis, and an adequate response rate (≥60%). (2) For case series, criteria included: standardized measurement and valid identification of the condition for all participants,

consecutive and complete inclusion of participants, reporting of participant demographics and clinical information, reporting of outcomes or follow-up results, reporting of the presenting site(s)/clinic(s) demographic information, and statistical analysis appropriate for case series studies. (3) For case reports, criteria included: clear description of patient demographic characteristics, patient history and timeline, current clinical condition on presentation, diagnostic tests/assessment methods and results, interventions/treatment procedures, post-intervention clinical condition, adverse/unanticipated events, and takeaway lessons.

Each criterion was scored as 1 (yes) or 0 (no or unclear). The overall risk of bias was categorized as low (>50%), moderate (>25-50%), or high (≤25%).

Outcome measurement

The primary outcomes of this systematic review and meta-analysis were Mpox severity and CFR. Mpox severity rate was determined by calculating the proportion of participants exhibiting severe or grave clinical manifestations of Mpox out of the total number of confirmed cases. CFR was calculated by dividing the number of deaths observed within the population of suspected or confirmed cases.

Operational definition

Severe or grave cases (requiring hospitalization), were defined by the presence of one or more of the following: extensive lesions (more than 100 lesions), hemorrhagic or pustular lesions, mucosal involvement (oral, genital, conjunctival), or systemic complications, including high fever (>39°C), altered general state (bedridden), sepsis, encephalitis, secondary bacterial infections, hypotension, septic shock, or severe dehydration, and keratitis leading to potential corneal scarring and blindness [8,28]. A suspected monkeypox case was defined as an individual

presenting with a vesicular or pustular rash characterized by deep-seated, firm pustules, and at least one of the following symptoms: fever preceding the eruption, lymphadenopathy (inguinal, axillary, or cervical), or pustules or crusts on the palms of the hands or soles of the feet. A case was defined as laboratory-confirmed Mpox if at least one specimen yielded a positive result in the *Orthopoxvirus*-specific assay, or Mpox-specific real-time PCR, or Mpox in culture [8].

Statistical analysis and synthesis

Heterogeneity between studies was assessed using the I^2 statistic. Heterogeneity was categorized as low (<25%), moderate (25-75%), or high (>75%). Subgroup analyses were conducted for study period, region, setting, method, study type/design, and disease burden. A random-effects model was employed when heterogeneity exceeded 50%. Meta-regression was performed to investigate whether study characteristics explained the variability in results across studies. For the severity rate subgroup analysis, the study characteristic examined was the year the study was conducted. Time frames for this analysis were defined based on key events in the DRC: (1) 1970–1980: pre-smallpox eradication era [15]; (2) 1981–1996: post-smallpox eradication era [11,29]; (3) 1997–2003: first major monkeypox outbreaks [30]; (4) 2004–2021: increased surveillance and reporting [31]; (5) 2022–2024: global outbreak and heightened response [32]. Similarly, time periods for assessing trends in CFR pooled estimates were established according to major developments in healthcare systems: (1) 1970–1990: limited healthcare infrastructure in endemic regions; (2) 1991–2010: improvements in healthcare access and disease surveillance; (3) 2011–2024: strengthened global health initiatives and response systems.

Only study variables with meaningful and practical categories were included in the analyses. Univariable and multivariable meta-regression models were used to assess whether

severity and CFRs varied according to the selected explanatory variable categories. Statistical significance was set at a p-value of <0.05. All analyses were performed using the 'meta' package in R Statistics version 4.4.2 [33].

Publication bias and sensitivity test

Publication bias was assessed visually using a funnel plot. Symmetry of the inverted funnel shape suggested the absence of publication bias. To further investigate potential bias, Egger's regression and Begg's rank correlation tests were performed, with statistical significance set at $p < 0.05$. Sensitivity analysis was conducted by iteratively excluding one study at a time to evaluate the robustness of the finding.

Results

A total of 127 records were retrieved from the database search (n = 122) and from other sources (n = 5). After removing 11 duplicate records, 114 records remained. Titles/abstracts, followed by full text articles were then screened for eligibility. Ultimately, 22 study reports met the eligibility criteria and were included in the meta-analysis (Fig. 1).

Studies selection



Fig. 1 PRISMA diagram flow of studies included in the meta-analysis

Characteristic of reports included

A comprehensive analysis included 22 studies. Those studies were conducted between 1970 and 2024 and involved population from community, hospital settings or both across

various regions in DRC. Most of studies used surveillance and investigation methodology for data collection and description (n = 20) (Additional Files 1, Supplementary Table 1)

Disease severity among confirmed Mpox cases

The overall pooled Mpox severity rate was 42.82% (95% CI: 31.60-54.05; I^2 = 95.7% and p<0.001) (Fig. 2). The subgroup analysis according to the study period underscores a progressive decline of Mpox severity rate from 68.58% (95% CI: 32.67-100.00, n = 2 studies) before 1980 to 27.55 (95% CI: 6.63-48.47, n = 5 studies). The highest severity rate was observed in Western/Central regions (46.81%, 95% CI: 30.28-63.33, n = 8 studies), however there was no significant difference between severity rate across regions. The severity rate was higher in study conducted within hospital settings (44.28%, 95% CI: 6.00-82.56, n = 2 studies) compared to community (42.59%, 95% CI: 30.28-54.90, n = 13 studies). Sites with lowest burden of Mpox confirmed cases (≤100) exhibited highest severity rate (55.54%, 95% CI: 31.10-79.97, n = 7 studies) (Table 1 and Additional Files 2, Supplementary Fig. 1-7).



Fig. 2 Pooled severity rate of Mpox case in DRC, 1970-2024

Table 1 Subgroup meta-analysis of Mpox severity rate pooled estimates in DRC, 1970-2024

Subgroup	Confirmed cases	Event rate[1] (%)	95% CI limits[1]		Number of studies	Heterogeneity statistic[1]	
			Lower	Upper		I^2(%)	*p*-value
Study period[2]							
≤1980	39	68.58	32.67	100.00	2	43.5	0.183
1981-1996	283	61.89	4.01	100.00	2	74.6	0.047
1997-2003	16	68.89	41.34	88.98	1	0	-
2004-2021	2161	43.81	31.04	56.58	5	96.3	<0.001
2022-2024	783	27.55	6.63	48.47	5	94.9	<0.001
Region[3]							
Northern	251	43.80	37.67	49.94	2	0	0.573
Western/Central	2200	46.81	30.28	63.33	8	94.7	<0.001
Eastern	549	42.66	6.79	78.52	4	91.6	<0.001
Nationwide	282	39.01	33.28	44.97	1	0	-
Setting							
Community	2635	42.59	30.28	54.90	13	94.7	<0.001
Hospital	647	44.82	6.00	82.56	2	99.0	<0.001
Method							
Surveillance and Investigation	2405	42.88	29.02	56.75	12	95.1	<0.001
Cross-sectional	877	44.25	22.08	66.41	3	98.1	<0.001
Study type/design							
Case report	2	100	57.57	100	2	0	1.000
Case series	2403	38.36	25.35	51.38	10	95.8	<0.001
Cross-sectional	877	44.25	22.08	66.41	3	98.1	<0.001
Disease burden (confirmed cases)							
≤100	91	55.54	31.10	79.97	7	80.8	<0.001
>100	3191	37.06	25.55	48.58	8	97.6	<0.001

[1]Random effects model; CI: Confidence Interval; [2]1970–1980: Pre-Smallpox Eradication Era; 1981–1996: Post-Smallpox Eradication Era; 1997–2003: First Major Monkeypox Outbreaks; 2004–2021: Increased Surveillance and Reporting; 2022–2024: Global Outbreak and Heightened Response; [3] Eastern: North and South Kivu; Northern: Bas-uélé and Tshopo; Western/Central: Equateur Kwango, Sankuru, Tshuapa)

Mortality among suspected Mpox cases

The pooled CFR among suspected Mpox cases was 1.89% (95% CI: 1.39-2.40; I^2 = 94.7% and p<0.001) (Fig. 3). The subgroup analysis revealed a decrease trend in CFR from 8.74%; (95% CI: 0.09-17.38, n = 5 studies) before 1991 to 1.28% (95% CI: 0.66-1.90, n = 13 studies) between 2011-2024. The high burden of mortality was recorded in Western regions (11.82%; 95% CI: 0.00-29.69, n = 11.82) and the lowest in Eastern regions (0.47%, 95% CI: 0.00-7.12). The CFR was

higher within community (0.47%, 95% CI: 0.00-7.12) compared to hospital settings (0.60%, 95% CI: 0.00-1.37). Localities with high burden of suspected cases (>500) presented lower CFR (3.44%, 95% CI: 1.63-5.25) (Table 2 and Additional Files 3, Supplementary Fig. 1-6).

Table 2 Subgroup meta-analysis of case fatality rate pooled estimates for suspected Mpox cases in DRC, 1970-2024

Subgroup	Suspected cases	Event rate[1] (%)	95% CI limits[1]		Number of studies	Heterogeneity statistic[1]	
			Lower	Upper		I^2(%)	*p*-value
Study period[2]							
≤1990	598	8.74	0.09	17.38	5	81.1	<0.001
1991-2010	12948	2.04	1.47	2.60	13	75.7	<0.001
2011-2024	73141	1.28	0.66	1.90	13	97.5	<0.001
Region[3]							
Western	44	11.82	0.00	29.69	3	28.7	0.241
Eastern	762	0.47	0.00	0.96	4	0	0.927
Nationwide	62221	3.46	0.00	7.12	4	99.0	<0.001
Central	821	1.45	0.63	2.26	4	0	0.526
Not reported	22681	1.76	1.29	2.23	14	81.4	<0.001
Northern	158	6.99	2.98	11.00	2	0	0.670
Setting							
Community	2418	3.04	0.75	5.34	12	78.2	<0.001
Community and Hospital	83533	1.94	1.44	2.43	16	95.4	<0.001
Hospital	736	0.60	0.00	1.37	3	0	0.506
Method							
Surveillance and Investigation	85954	2.01	1.47	2.54	29	94.7	<0.001
Cross-sectional	733	0.60	0.00	1.37	2	26.6	0.243
Study type/design							
Case report	2	0.00	0.00	42.43	2	0	1.000
Case series	85952	2.01	1.47	2.54	27	95.1	<0.001
Cross-sectional	733	0.60	0.00	1.37	2	26.6	0.243
Disease burden (suspected cases)							
≤500	2220	3.44	1.63	5.25	15	67.8	<0.001
>500	84467	1.61	1.12	2.10	16	97.1	<0.001

[1]Random effects model; CI: Confidence Interval; [2]1970–1990: Limited healthcare infrastructure in endemic regions; 1991-2010: Improvements in healthcare access and disease surveillance; 2011-2024: Strengthened global health initiatives and response systems; [3] Eastern: North Kivu and South Kivu; Central: Kasai Oriental and Sankuru; Northern DRC: North Ubangui and Tshopo; Western: Equateur and Kwango)



Fig. 3 Pooled case fatality rate for suspected Mpox case in DRC, 1970-2024

Mortality among confirmed Mpox cases

The pooled CFR among confirmed Mpox cases was 4.18% (95% CI: 0.29-8.08; I^2 = 80.6% and p<0.001) (Fig. 4). The subgroup analysis revealed the CFR decrease in DRC from 8.74%; (95% CI: 0.09-17.38, n = 5 studies) before 1991 to 0.28% (95% CI: 0.02-0.54, n = 5 studies) between 2011-2024. The high burden of mortality was observed in Western/Central regions (11.37%; 95%

CI: 0.00-24.65, *n* = 5 studies) and the lowest in Eastern regions (0.46%, 95% CI: 0.00-1.10, *n* = 3 studies). The CFR was higher within community (6.66%, 95% CI: 0.35-12.97, *n* = 9 studies) compared to hospital settings (0.64%, 95% CI: 0.00-1.36, *n* = 2 studies). Localities with high burden of suspected cases (>40) presented lower CFR (2.47%, 95% CI: 0.00-5.50, *n* = 5 studies) (Table 3 and Additional Files 4, Supplementary Fig. 1-6).



Fig. 4 Pooled case fatality rate for confirmed Mpox case in DRC, 1970-2024

Table 3 Subgroup meta-analysis of case fatality rate pooled estimates for confirmed Mpox cases in DRC, 1970-2024

Subgroup	Confirmed cases	Event rate[1] (%)	95% CI limits[1]		Number of studies	Heterogeneity statistic[1]	
			Lower	Upper		I^2(%)	*p*-value
Study period[2]							
≤1990	598	8.74	0.09	17.38	5	81.1	<0.001
1991-2010	16	31.25	11.02	58.66	1	0	-
2011-2024	1627	0.28	0.02	0.54	5	0	0.644
Region[3]							
Western/Central	276	11.37	0.00	24.65	5	73.7	0.004
Eastern	441	0.46	0.00	1.10	3	0	0.998
Nationwide	1524	3.76	0.00	9.17	3	93.9	<0.001
Setting							
Community	1594	6.66	0.35	12.97	9	84.0	<0.001
Hospital	647	0.64	0.00	1.36	2	13.3	<0.001
Method							
Surveillance and Investigation	1594	6.66	0.35	12.97	9	84.0	<0.001
Cross-sectional	647	0.64	0.00	1.36	2	13.3	0.283
Study type/design							
Case report	2	0.00	0.00	42.43	2	0	1.000
Case series	1592	6.90	0.31	13.48	7	88.0	<0.001
Cross-sectional	647	0.64	0.00	1.36	2	13.3	0.282
Disease burden (confirmed cases)							
≤40	70	11.47	0.00	97.50	6	45.0	0.105
>40	2171	2.47	0.00	5.50	5	80.6	<0.001

[1]Random effects model; CI: Confidence Interval; [2]1970–1990: Limited healthcare infrastructure in endemic regions; 1991-2010: Improvements in healthcare access and disease surveillance; 2011-2024: Strengthened global health initiatives and response systems; [3] Eastern: North Kiyu and South Kiyu; Central: Kasai Oriental and Sankuru; Western: Equateur and Kwango

Meta-regression analysis

Univariate analysis revealed that study year and region were significant sources of heterogeneity for the examined health indicators. In the multivariate analysis, study year was a significant source of heterogeneity ($p < 0.001$), with suspected CFRs decreasing as years increased (β = -4.18%). Additionally, the region where the study was conducted significantly

influenced the study outcomes (p = 0.03). Specifically, confirmed Mpox CFRs were higher in the Western/Central regions compared to other regions (β = 1.7037) (Table 4).

Table 4 Univariate and multivariate meta-regression analysis of Mpox disease outcome metrics in DRC, 1970-2024

Epidemiological estimate	Moderator	Univariate		Multivariate	
		Unadjusted coefficient (β)	*p*-value	Adjusted coefficient (β)	*p*-value
Severity rate					
Study year	Years	-0.0256	0.053	-0.0281	0.060
Region	Western/Central vs Others	0.6035	0.165	0.5763	0.207
Method	SIR vs Cross-sectional	-0.1144	0.837	-0.9959	0.225
Setting	Hospital vs Community	0.0834	0.897	-0.5156	0.563
Suspected case fatality rate					
Study year	Years	-0.0486	< 0.001	-0.0418	< 0.001
Region	Not reported vs Reported	-0.6390	< 0.001	-0.5763	0.048
Method	SIR vs Cross-sectional	1.1456	0.1355	2.9944	0.085
Setting	Hospital vs Others	-0.6648	0.3508	2.0020	0.226
Confirmed case fatality rate					
Study year	Years	-0.0633	0.010	-0.0418	0.084
Region	Western/Central vs Others	1.7911	0.093	1.7037	0.030
Method	SIR vs Cross-sectional	2.2626	0.0873	1.480	0.173
Setting[1]	Hospital vs Community	-2.2626	0.0873	-	-

[1] *Redundant predictor dropped from the model*

Publication bias and sensitivity test analysis

A large and almost symmetrical distribution of data points was observed in the funnel plot suggesting a low risk of publication bias for all the outcome interest. In addition, the Egger's linear regression and Begg's rank correlation tests confirmed the absence of statistically significant publication bias (Additional Files 2, Supplementary Fig. 9; Additional Files 3, Supplementary Fig. 8, and Additional Files 4, Supplementary Fig. 8).

Sensitivity analysis, assessing the impact of individual studies and outliers on the overall results, demonstrated that no study exerted a significant impact on the overall pooled estimate (Additional Files 2, Supplementary Fig. 8; Additional Files 3, Supplementary Fig. 7, and Additional Files 4, Supplementary Fig. 7).

Discussion

This systematic review and meta-analysis were conducted to determine the Mpox severity and CFRs in the world most endemic focus. It synthesized data from 22 studies to provide a comprehensive overview of Mpox severity and mortality in the DRC from 1970 to 2024. The analysis revealed an overall pooled Mpox severity rate of 42.82% and a pooled CFR among suspected Mpox cases of 1.89%.

Severity rate

The observed pooled severity rate of 42.82% (95% CI: 31.60-54.05; I^2 = 95.7% and p<0.001) highlights the substantial clinical burden of Mpox in the DRC. This finding is consistent with previous reports that have documented a range of severity in Mpox cases, with some individuals experiencing mild, self-limiting illness and others developing severe complications [1,8]. A study in the United Kingdom estimated the risk of hospitalization among 90,439 laboratory-confirmed Mpox cases to be between 3.53% (95% Confidence Interval [CI]: 2.20-5.60) and 9.43% (95% CI: 5.18-16.57) [34]. This was lower than the proportion observed in our study. Factors such as host immunity, viral strain, and access to care probably influence the observed differences in disease severity [30]. Evidence indicates that infections with viral lade 1a result in more severe disease than infections with other clades [3].

A notable trend observed in the subgroup analysis was the progressive decline in Mpox severity rate over time, from 68.58% before 1980 to 27.55% between 2022 and 2024. This decline may reflect potential changes in the circulating viral strains or improvements in healthcare infrastructure, increased surveillance and reporting. Current evidence highlights the identification in 2023 of a newly discovered clade 1b through genomic analysis of strains from previously non-endemic provinces in the eastern DRC. This clade might exhibit less virulence than the classical clade 1a strain [35]. However, it is important to interpret this trend with caution, as heterogeneity across studies and variations in case definitions could also influence these findings.

Regional variations in Mpox severity were also evident, with the highest severity rate observed in the Western/Central regions (46.81%). While this difference was not statistically significant, it may suggest the influence of region-specific factors on disease presentation and outcomes. The Western/Central DRC is endemic for the Congo Basin clade of mpox virus, which has been associated with higher virulence and more severe clinical outcomes compared to the West African clade [36,37]. The existence of comorbidities like HIV could exacerbate Mpox severity, as underscored by a study in Nigeria and other African countries where the high prevalence and non-suppression of HIV/AIDS increases the risk of severe outcomes for Clade 1 Mpox virus infection [38,39]. Further research is needed to explore these regional disparities and identify potential risk factors for severe Mpox in specific areas.

To effectively address the ongoing Mpox threat, a multi-faceted approach is essential. Community-based interventions, including the deployment of mobile health units, implementation of community education programs, and provision of early diagnostic tools, are

crucial to reducing delays in care-seeking and improving outcomes, particularly given the observed high severity of Mpox in community settings.

Case fatality rate

The pooled CFR among suspected Mpox cases was 1.89% (95% CI: 1.39-2.40; I^2 = 94.7% and p<0.001), with a decreasing trend observed over time. This finding aligns with previous studies that have reported CFRs for Mpox generally ranging from 0% to 12% [3]. The pooled CFR for confirmed Mpox cases in this analysis was 4.18% (95% CI: 0.29–8.08), exhibiting significant heterogeneity (I^2 = 80.6%, p < 0.001). This result corroborates findings reported in an African study, where 45,652 Mpox cases, clinically diagnosed and laboratory-confirmed across 12 African countries, resulted in 1492 deaths (CFR, 3.3%) [40]. The high heterogeneity suggests substantial variability in CFR across the included studies, which can likely be attributed to several factors, including temporal shifts, regional disparities, and differences in healthcare settings.

A notable trend observed was the decline in CFR over time. The CFR was considerably higher (8.74%) in studies conducted before 1991, likely reflecting the limited healthcare access and absence of Mpox-specific interventions during that period. The cessation of smallpox vaccination campaigns around 1980 may have also contributed to increased susceptibility to Mpox, particularly in older cohorts [15]. In contrast, the CFR decreased significantly to 0.28% in studies conducted between 2011 and 2024. This decline aligns with improvements in surveillance, earlier case detection, and enhanced supportive care [32]. However, it is important to acknowledge that potential underreporting of milder Mpox cases in recent years could introduce a downward bias in the CFR estimates.

Regional disparities also played a significant role in the observed heterogeneity. The Western/Central regions of the DRC exhibited a substantially higher CFR (11.37%) compared to the Eastern regions (0.46%). This difference may be attributed to the predominance of the more virulent Congo Basin clade in the Western/Central DRC and the presence of rural healthcare gaps that contribute to delays in seeking and receiving appropriate treatment. In contrast, the Eastern DRC generally has better urban healthcare infrastructure, which may contribute to improved outcomes. Additionally, the possibility of cross-protection from Ebola vaccination campaigns in the Eastern DRC as a contributing factor to the lower CFR in that region should be also explored [41,42].

Furthermore, the healthcare setting influenced the CFR. Community settings were associated with a higher CFR (6.66%) compared to hospital settings (0.64%). This finding likely reflects factors such as late presentation, misdiagnosis, and the use of traditional medicine in community settings, which can exacerbate disease outcomes. Study reports establish that traditional African Medicine remains an important health care resource among population in DRC [43]. On the other hand, hospital settings offer access to supportive care, such as fluid management and antibiotics for secondary bacterial infections, which can reduce mortality.

Interestingly, localities with a high burden of confirmed Mpox cases (>40 cases) demonstrated a lower CFR (2.47%). This seemingly counterintuitive finding may be explained by enhanced awareness leading to earlier case identification and reporting, as well as more efficient resource allocation and targeted interventions, such as vaccination and healthcare worker training, in high-burden areas [32]. The findings of this review have several implications for research and public health policy. There is a clear need for targeted interventions in the

Western/Central DRC, including healthcare strengthening initiatives such as mobile clinics to reach remote populations and the potential use of strain-specific vaccines given the virulence of the Congo Basin clade.

Strength and Limitations

This review has several limitations. First, some death cases might have been unreported due to study design, potentially underestimating the true CFR. Second, the high degree of heterogeneity observed across studies, particularly in the severity rate analysis, may limit the generalizability of the findings. Confounding by strain differences remains a concern, as the lack of comprehensive genomic data in many studies obscures the clade-specific mortality rates. Surveillance bias, particularly the potential for improved detection of milder cases in more recent studies, may also influence the CFR estimates. Additionally, the small sample sizes in some subgroup analyses result in wide confidence intervals, limiting the precision of the findings. Despite these limitations, this systematic review and meta-analysis provides valuable insights into Mpox severity and mortality in the DRC. The findings highlight the continued public health importance of Mpox in the region and underscore the need for ongoing surveillance, research, and interventions to reduce the burden of this disease

Conclusions

This systematic review and meta-analysis provide a comprehensive assessment of Mpox severity and mortality in the DRC from 1970 to 2024.The pooled analyses revealed an overall Mpox severity rate of 42.82% and a CFR of 4.18% among suspected Mpox cases. Subgroup analyses and meta-regression identified significant temporal and regional variations in these

outcomes, highlighting the complex and evolving epidemiology of Mpox in the DRC. Despite the limitations inherent in the available data, this study underscores the continued public health burden of Mpox in the DRC and emphasizes the need for sustained surveillance, research, and targeted interventions to mitigate its impact. The disproportionately high severity rates in the DRC underscore the urgent need for global health equity, necessitating increased international support for vaccine distribution, healthcare workforce training, and laboratory capacity building within the country. Strengthening of community engagement strategies to address delays in care-seeking behaviors through education and awareness campaigns is also crucial. Furthermore, genomic surveillance should be considered among priorities to clarify the contribution of different Mpox clades to disease severity and mortality.

Abbreviations

CFR: Case Fatality Rate

CI: Confidence Interval

DRC: Democratic Republic of Congo

HCW: Healthcare worker

HIV/AIDS: Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome

MeSH: Medical Subject Headings

PCR: Polymerase Chain Reaction

PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis

Declarations

Author contributions: F.Z.L.C. conceived the original idea of the study. F.Z.L.C. and A.Z. conducted the literature search. F.Z.L.C., A.Z. and S.N. selected the studies, extracted the relevant information, and synthesized the data. F.Z.L.C. performed the analyses and wrote the first draft of the manuscript. All authors critically reviewed and revised successive drafts of the manuscript. All authors read and approved the final manuscript.

Ethical Approval Statement: Not applicable

Consent for publication: Not applicable.

Availability of data and materials: The sources of data supporting this systematic review are available in the reference. All data generated or analyzed during this study are included in this published article and supplemental material.

Competing interests: All authors declare no conflicts of interest and have approved the final version of the article.

Funding source: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

References

1. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox—A potential threat? A systematic review. Gromowski G, editor. *PLoS Negl Trop Dis*. 2022;16(2):e0010141.

2. Shchelkunova GA, Shchelkunov SN. Smallpox, Monkeypox and Other Human Orthopoxvirus Infections. *Viruses*. 2022;15(1):103.

3. Beiras CG, Malembi E, Escrig-Sarreta R, Ahuka S, Mbala P, Mavoko HM, et al. Concurrent outbreaks of mpox in Africa—an update. *The Lancet*. 2025;405(10472):86–96.

4. Cadmus S, Akinseye V, Besong M, Olanipekun T, Fadele J, Cadmus E, et al. Dynamics of Mpox infection in Nigeria: a systematic review and meta-analysis. *Sci Rep*. 2024;14(1):7368.

5. Subissi L, Mitjà O. Rising mpox trends in DR Congo: the neglected spread of an epidemic. *The Lancet*. 2025;405(10476):358–60.

6. Bangwen E, Diavita R, Vos ED, Vakaniaki EH, Nundu SS, Mutombo A, et al. Suspected and confirmed mpox cases in DR Congo: a retrospective analysis of national epidemiological and laboratory surveillance data, 2010–23. *The Lancet*. 2025;405(10476):408–19.

7. Su S, Jia M, Yu Y, Li H, Yin W, Lu Y, et al. Integrated Network Analysis of Symptom Clusters Across Monkeypox Epidemics From 1970 to 2023: Systematic Review and Meta-Analysis. *JMIR Public Health Surveill*. 2024;10: e49285.

8. Whitehouse ER, Bonwitt J, Hughes CM, Lushima RS, Likafi T, Nguete B, et al. Clinical and Epidemiological Findings from Enhanced Monkeypox Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011–2015. *J Infect Dis*. 2021;223(11):1870–8.

9. Breman JG, Kalisa-Ruti null, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-79. *Bull World Health Organ*. 1980;58(2):165–82.

10. Mwanba PT, Tshioko KF, Moudi A, Mukinda V, Mwema GN, Messinger D, et al. Human monkeypox in Kasaï Oriental, Zaire (1996-1997). Eurosurveillance. 1997;2(5):33–5.

11. Hutin YJF, Williams RJ, Malfait P, Pebody R, Loparev VN, Ropp SL, et al. Outbreak of Human Monkeypox, Democratic Republic of Congo, 1996 to 1997. *Emerg Infect Dis*. 2001;7(3):434–8.

12. Dieu-Merci. KY, Singa Valentin. B, Ley. BL, Antoine. ET, Guild. AK, Lwanga. K, et al. MPOX: EPIDEMIOLOGICAL PROFILE AND FACTORS ASSOCIATED WITH ITS EMERGENCE IN THE ISANGI TERRITORY, DEMOCRATIC REPUBLIC OF CONGO. *Int J Appl Sci Eng Rev*. 2024;5(5):27–43.

13. Kibungu EM, Vakaniaki EH, Kinganda-Lusamaki E, Kalonji-Mukendi T, Pukuta E, Hoff NA, et al. Clade I–Associated Mpox Cases Associated with Sexual Contact, the Democratic Republic of the Congo. *Emerg Infect Dis*. 2024;30(1):172–6.

14. Matusali G, Petruccioli E, Cimini E, Colavita F, Bettini A, Tartaglia E, et al. Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination. *Vaccines*. 2023;11(10):1541.

15. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID, Organization WH. Smallpox and its eradication. World Health Organization; 1988. https://iris.who.int/handle/10665/39485. Accessed: 2025 Mar 30.

16. Doshi RH, Guagliardo SAJ, Dzabatou-Babeaux A, Likouayoulou C, Ndakala N, Moses C, et al. Strengthening of Surveillance during Monkeypox Outbreak, Republic of the Congo, 2017. *Emerg Infect Dis*. 2018;24(6):1158–60.

17. Marou V, Vardavas CI, Aslanoglou K, Nikitara K, Plyta Z, Leonardi-Bee J, et al. The impact of conflict on infectious disease: a systematic literature review. *Confl Health*. 2024;18(1):27.

18. Musuka G, Moyo E, Tungwarara N, Mhango M, Pierre G, Saramba E, et al. A critical review of mpox outbreaks, risk factors, and prevention efforts in Africa: lessons learned and evolving practices. *IJID Reg*. 2024;12(2024):100402.

19. Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLOS Med*. 2009;6(7): e1000097.

20. Congo, Democratic Republic of the. In: The World Factbook. Central Intelligence Agency; 2023. https://www.cia.gov/the-world-factbook/countries/congo-democratic-republic-of-the/. Accessed:2023 Oct 30.

21. République démocratique du Congo - Plan national de développement sanitaire recadré pour la période 2019-2022 : Vers la Couverture sanitaire universelle. https://www.ilo.org/dyn/natlex/natlex4.detail?p_isn=111796&p_lang=fr. Accessed :2023 Oct 30.

22. Democratic Republic of the Congo. WHO, Geneva. 2024 https://data.who.int/countries/180. Accessed:2025 Mar 27.

23. Amani A, Bene ACM, Lungoyo CL, Mukoka AK, Cheuyem FZL, Mpinganjira S, et al. The Struggle to Vaccinate: Unveiling the Reality of the first year of Covid-19 Vaccination in the Democratic Republic of Congo. *medRxiv*; 2024. doi: 10.1101/2024.01.03.24300795v1.

24. Overview. World Bank. https://www.worldbank.org/en/country/drc/overview. Accessed: 2023 Oct 30.

25. Priest RJ, Ngolo A, Stabell T. Christian Pastors and Alleged Child Witches in Kinshasa, DRC. *OKH J Anthropol Ethnogr Anal Eyes Christ Faith*. 2020;4(1):2–51.

26. Democratic Republic of the Congo situation. UNHCR, Global Focus, Geneva. 2024. https://reporting.unhcr.org/operational/situations/democratic-republic-congo-situation. Accessed: 2025 Apr 6.

27. JBI Critical Appraisal Tools. The Joanna Briggs Institute, Adelaide. 2017. https://jbi.global/critical-appraisal-tools. Accessed: 2024 Dec 3.

28. Breman JG, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-79. *Bull World Health Organ*. 1980;58(2):165.

29. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M. Human Monkeypox: Clinical Features of 282 Patients. *J Infect Dis*. 1987;156(2):293–8.

30. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. *Proc Natl Acad Sci*. 2010;107(37):16262–7.

31. Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. *Lancet Infect Dis*. 2004;4(1):15–25.

32. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022. *N Engl J Med*. 2022;387(8):679–91.

33. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. 2024. https://www.R-project.org/. Accessed:2024 Dec 19.

34. Ward T, Overton CE, Paton RS, Christie R, Cumming F, Fyles M. Understanding the infection severity and epidemiological characteristics of mpox in the UK. *Nat Commun*. 2024;15(1):2199.

35. Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O'Toole Á, Wawina-Bokalanga T, Mukadi-Bamuleka D, et al. Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. *Nat Med*. 2024;30(10):2791–5.

36. Chen N, Li G, Liszewski MK, Atkinson JP, Jahrling PB, Feng Z, et al. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. *Virology*. 2005;340(1):46–63.

37. Likos AM, Sammons SA, Olson VA, Frace AM, Li Y, Olsen-Rasmussen M, et al. A tale of two clades: monkeypox viruses. *J Gen Virol*. 2005;86(Pt 10):2661–72.

38. Ogoina D, Yinka-Ogunleye A. Sexual history of human monkeypox patients seen at a tertiary hospital in Bayelsa, Nigeria. *Int J STD AIDS*. 2022;33(10):928–32.

39. Bosa HK, Muttamba W, Bakamutumaho B, Rwagasore E, Runumu J, Bbuye M, et al. High prevalence and non-suppression of HIV/AIDS in the East and Central African region heightens risk of severe outcomes for Clade I monkeypox virus infection, and may be a driver for subsequent adaptation. *IJID One Health*. 2025;6:100050.

40. Ndembi N, Folayan MO, Komakech A, Mercy K, Tessema S, Mbala-Kingebeni P, et al. Evolving Epidemiology of Mpox in Africa in 2024. *N Engl J Med*. 2025;392(7):666–76.

41. Muyembe JJ, Pan H, Peto R, Diallo A, Touré A, Mbala-Kingebene P, et al. Ebola Outbreak Response in the DRC with rVSV-ZEBOV-GP Ring Vaccination. *N Engl J Med*. 2024;391(24):2327–36.

42. Adepoju P. Ring vaccination effective in containing Ebola. *Nat Afr*. 2025. doi: 10.1038/d44148-025-00024-5

43. Mutombo CS, Bakari SA, Ntabaza VN, Nachtergael A, Lumbu JBS, Duez P, et al. Perceptions and use of traditional African medicine in Lubumbashi, Haut-Katanga province (DR Congo): A cross-sectional study. *PLoS ONE*. 2022;17(10):e0276325.